Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Journal of clinical gastroenterology - 1 Apr 2015

Flamm Steven L, Muir Andrew J, Fried Michael W, Reddy K Rajender, Nelson David R, Bzowej Natalie H, Sullivan James C, Bengtsson Leif, DeMasi Ralph, Wright Christopher I, Kieffer Tara L, George Shelley, Adda Nathalie, Dusheiko Geoffrey M

Abstract excerpt

BACKGROUND: The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of race and ethnicity on treatment response. However, these factors are important given the lower sustained virologic response (SVR) rates observed in black and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 24828357
DOI: 10.1097/MCG.0000000000000150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.PMID 24828357Read ↗

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.Semantic proximity Read ↗

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.Semantic proximity Read ↗

Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.Semantic proximity Read ↗

The impact of ethnicity on hepatitis C virus treatment decisions and outcomes.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.